ACHP Calls for Hearings on High-Cost Cell and Gene Therapies

The Alliance of Community Health Plans (ACHP) sent a letter to key Congressional committee leaders urging hearings on the high-cost cell and gene therapies rapidly gaining FDA approval. ACHP recognizes that these new treatments will require changes to how we think about coverage and payment and calls on Congress to engage to balance the need for patient access with the high up-front prices of these therapies.